Table 3.
Comparison of platelet VEGF and plasma sVEGFR-2 per treatment groups in the CENTAURO-2 trial
| Groups | pg of VEGF/106platelets Mean (range) [n] |
pg/mL of sVEGFR-2 Mean (range) [n] |
||
|---|---|---|---|---|
| Week 0 | Week 13 | Week 0 | Week 13 | |
| Ag + V | 1.21 (0.30–2.20) [7] |
0.61 (0.10–1.43) [7] ns |
9736 (6939–11724) [7] |
9792 (7427–11162) [7] ns |
| Ag + 2 V | 0.93 (0.55–1.46) [7] |
1.01 (0.08–3.29) [7] ns |
10455 (8116–12653) [8] |
10423 (7262–12882) [8] ns |
| 2Ag + V | 2.07 (0.11–8.19) [8] |
0.57 (0.22–2.05) [8] p = 0.0244* |
9736 (7078–12637) [8] |
9948 (9125–11098) [8] ns |
| ½Ag + Al | 1.90 (0.90–3.64) [8] |
1.98 (0.63–3.54) [8] ns |
10228 (7555–12735) [8] |
9567 (7820–13372) [8] ns |
| Ag + Al | 1.58 (0.72–3.19) [8] |
1.06 (0.15–2.91) [8] p = 0.0086** |
10131 (8491–12223) [8] |
10296 (8611–13294) [8] ns |
The table summarizes the data per vaccine dose cohorts and the results of paired t-test (ns: non-significant; *p < 0.05; **p < 0.01). (n) number of patients